Stock Events

FibroGen 

M$19.08
47
+M$0.55+2.97% Thursday 18:19

Statistics

Day High
19.08
Day Low
19.08
52W High
341.2
52W Low
13.85
Volume
21
Avg. Volume
451
Mkt Cap
36.76B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

6MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.98
-0.76
-0.55
-0.33
Expected EPS
-0.42
Actual EPS
-0.33

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FGEN.MX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Show more...
CEO
Mr. Enrique A. Conterno
Employees
566
Country
United States
ISIN
US31572Q8087
WKN
000A12EZ0

Listings